Alsatinib 50mg Tablet

About

Alsatinib 50mg Tablet is an oral targeted therapy medication classified as a tyrosine kinase inhibitor (TKI), primarily used in the treatment of various cancers. This drug works by selectively inhibiting specific tyrosine kinases that are crucial for cancer cell growth, proliferation, and survival. By blocking these aberrant signaling pathways, Alsatinib effectively halts or slows the progression of tumors that are dependent on these kinases. It is often indicated for cancers with specific genetic mutations or overexpression of target proteins, allowing for a more personalized and effective treatment approach compared to traditional chemotherapy. The 50mg dosage is typically part of a carefully titrated regimen, reflecting the potency of the compound and the need to balance therapeutic efficacy with managing potential side effects. Regular monitoring of patient response and adverse events is essential to optimize treatment outcomes and ensure patient safety throughout the course of therapy.

Uses

• Treatment of specific types of solid tumors.
• Management of certain hematological malignancies.
• Targeted therapy for cancers with specific genetic mutations.
• Disease control in advanced or metastatic cancer.

Directions For Use

Take orally once daily with or without food, as directed by your oncologist. Do not crush, chew, or break the tablet.

Benefits

• Targets specific cancer pathways, leading to higher efficacy.
• Oral administration offers convenience for patients.
• May improve progression-free survival in responsive cancers.
• Potentially fewer systemic side effects than traditional chemotherapy.
• Effective in cancers with specific genetic markers.
• Offers a personalized treatment approach.

Side Effects

• Fatigue.
• Nausea and vomiting.
• Diarrhea.
• Rash.
• Hand-foot syndrome.
• Hypertension (high blood pressure).
• Headache.
• Edema (swelling).
• Abdominal pain.
• Changes in liver function tests.
• Myelosuppression (low blood counts).
• QT prolongation (cardiac effect).

Safety Measures

• Alcohol - Avoid or limit alcohol consumption as it may exacerbate liver-related side effects or interact with the medication's metabolism.
• Pregnancy - Contraindicated; Alsatinib can cause fetal harm. Women of childbearing potential must use effective contraception during and after treatment.
• Breastfeeding - Not recommended; it is unknown if Alsatinib is excreted in human milk and could harm a breastfed infant. Discontinue breastfeeding.
• Liver - Use with caution in patients with hepatic impairment; dose adjustments are often required, and liver function should be closely monitored.
• Kidney - Administer with caution in patients with renal impairment; dose adjustments may be necessary based on the degree of kidney dysfunction.
• Lung - Monitor for new or worsening respiratory symptoms (e.g., interstitial lung disease), especially in patients with pre-existing lung conditions.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.